Day One Biopharmaceuticals
Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week.
Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of brain cancer. DAY101 is a Phase 2-ready RAF inhibitor that also shows strong potential for other pediatric and adult indications.
The company is co-founded by Chief Medical Officer Dr. Sam Blackman (who offered our May webinar) and Acting CEO Julie Grant from Canaan Partners.
You can read more here.
Please look for a planned CAC2 webinar later this year with representatives from Day One, OncoHeroes, and other companies devoting resources to developing drugs for children with cancer.
Categories
- Blog Posts (114)
- Explainer Post (12)
- Guest Blogs (27)
- Member Blogs (42)
- Survivorship Matters Blog (9)
- CAC2 News (23)
- Collaborative Achievements (15)
- Community News (271)
- In Memoriam (2)
- News Digest (220)
- Webinars (64)
Tags
Recent Posts
- CAC2 Childhood Cancer Community News Digest (March 17-23)
- CAC2 Childhood Cancer Community News Digest (March 10-16)
- Member Blog–Awareness & Entertainment Opportunity: Audrey’s Children
- CAC2 Childhood Cancer Community News Digest (March 3-9)
- CAC2 Childhood Cancer Community News Digest (February 28-March 2)